These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31993861)

  • 1. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Qian XL; Xu P; Zhang YQ; Song YM; Li YQ; Li WD; Jiang CY; Shen BB; Zhang XM; Zhang LN; Fu L; Guo XJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):311-319. PubMed ID: 31993861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy.
    Malone MK; Smrekar K; Park S; Blakely B; Walter A; Nasta N; Park J; Considine M; Danilova LV; Pandey NB; Fertig EJ; Popel AS; Jin K
    Cancer Biol Ther; 2020 Jun; 21(6):560-569. PubMed ID: 32213106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
    Kajihara N; Kitagawa F; Kobayashi T; Wada H; Otsuka R; Seino KI
    Breast Cancer; 2020 Nov; 27(6):1198-1204. PubMed ID: 32578004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration.
    Khalid F; Takagi K; Sato A; Yamaguchi M; Guestini F; Miki Y; Miyashita M; Hirakawa H; Ohi Y; Rai Y; Sagara Y; Sasano H; Suzuki T
    Breast Cancer; 2023 Sep; 30(5):748-757. PubMed ID: 37178415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study.
    Sultana R; Kataki AC; Barthakur BB; Sarma A; Bose S
    Curr Probl Cancer; 2020 Oct; 44(5):100556. PubMed ID: 32044043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
    Jiang F; Li Y; Si L; Zhang Z; Li Z
    Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
    Sahin Ozkan H; Ugurlu MU; Yumuk PF; Kaya H
    Pathol Oncol Res; 2020 Oct; 26(4):2733-2745. PubMed ID: 32681436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic risk model for patients with triple negative breast cancer based on stromal natural killer cells, tumor-associated macrophages and growth-arrest specific protein 6.
    Tian W; Wang L; Yuan L; Duan W; Zhao W; Wang S; Zhang Q
    Cancer Sci; 2016 Jul; 107(7):882-9. PubMed ID: 27145494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
    Wang K; Shen T; Siegal GP; Wei S
    Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
    Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
    Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of MTDH and VEGF in triple-negative breast cancer].
    Tan L; Qin H; Piao Y; Liu Z; Han Y; Song F; Xie X
    Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):827-32. PubMed ID: 26887512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis.
    Tsai YF; Huang CC; Lin YS; Hsu CY; Huang CP; Liu CY; Chiu JH; Tseng LM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2339-2351. PubMed ID: 33512556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.